Home The Word Brain My Amedeo FAQ Privacy About   


Amedeo C49

English + 你好 (nǐ hǎo) = limitless possibilities.
Start learning Mandarin Chinese today—for free, forever.

Amedeo C49 is completely free, for life. Next week: +49.


  Chronic Heart Failure

  Free Subscription


Articles published in Am Heart J

Retrieve available abstracts of 100 articles:
HTML format



Single Articles


    November 2025
  1. DEVASENAPATHY N, Biswas S, Kini P, Satheesh S, et al
    Digoxin in rheumatic heart disease: Rationale and design of a multicenter, placebo-controlled double-blind randomized controlled trial (Dig-RHD trial).
    Am Heart J. 2025;289:38-47.
    PubMed     Abstract available


    October 2025
  2. RAMBARAT P, Erickson T, Cyr D, Ward J, et al
    Effects of angiotensin-neprilysin inhibition in women vs men: Insights from PARAGLIDE-HF.
    Am Heart J. 2025;288:41-51.
    PubMed     Abstract available


    July 2025
  3. ILONZE OJ, Helmkamp LJ, McIlvennan CK, Allen LA, et al
    Trends in Urine Drug Screening and Positivity Among Patients with Heart Failure: Insights from a Large Health System.
    Am Heart J. 2025 Jul 10:S0002-8703(25)00216-9. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available


  4. KARSTEN M, Vignati C, Pezzuto B, Apostolo A, et al
    Accurate Fick cardiac output estimation: direct and simultaneous oxygen consumption measurement is imperative in heart failure.
    Am Heart J. 2025 Jul 9:S0002-8703(25)00209-1. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available


    June 2025
  5. HANIF M, Khan LA, Kulkarni A, Bhatia HS, et al
    Global lipoprotein (a) testing trends from 2015 to 2023.
    Am Heart J. 2025 Jun 21:S0002-8703(25)00199-1. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available


  6. ZIMERMAN A, Dal Forno A, Rohde LE, Ternes CMP, et al
    Conduction System Pacing vs. Biventricular Resynchronization in Heart Failure With Reduced Ejection Fraction and Left Bundle Branch Block: Rationale and Design of the PhysioSync-HF Trial.
    Am Heart J. 2025 Jun 3:S0002-8703(25)00191-7. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available


  7. KHAN MS, Sauer AJ, Green CL, McDermott J, et al
    Rationale, Design, and Baseline Characteristics of the Virtual Care to Improve Heart Failure Outcomes (VITAL-HF) Trial.
    Am Heart J. 2025 Jun 3:S0002-8703(25)00190-5. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available


    May 2025
  8. KITTIPIBUL V, Cyr DD, Harrington J, Lala A, et al
    Structural Abnormalities and Effects of Sacubitril/Valsartan in Patients with Mildly Reduced or Preserved Ejection Fraction and Worsening Heart Failure: The PARAGLIDE-HF Trial.
    Am Heart J. 2025 May 22:S0002-8703(25)00161-9. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available


  9. SZABO-SODERBERG B, Benson L, Savarese G, Hage C, et al
    Loop and thiazide diuretics and outcomes in heart failure with preserved ejection fraction.
    Am Heart J. 2025 May 6:S0002-8703(25)00155-3. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available


    April 2025
  10. KITTIPIBUL V, Novelli A, Yaranov D, Swavely A, et al
    Relationship of Red Blood Cell Mass Profiles and Anemia Type to Outcomes and Cardiopulmonary Exercise Performance in Chronic Heart Failure.
    Am Heart J. 2025 Apr 28:S0002-8703(25)00143-7. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available


  11. PETERS AE, Li S, Cyr D, Williamson KM, et al
    Influence of ejection fraction on outcomes with sacubitril/valsartan in patients with worsening heart failure with EF>40%: The PARAGLIDE-HF Trial.
    Am Heart J. 2025 Apr 21:S0002-8703(25)00139-5. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available


  12. DUPRE ME, Dhingra R, Xu H, Hammill BG, et al
    Racial and ethnic disparities in longitudinal trajectories of hospitalizations in patients diagnosed with heart failure.
    Am Heart J. 2025 Apr 8:S0002-8703(25)00123-1. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available


    March 2025
  13. CHEN Y, Lawrence J, Stockbridge N
    Corrigendum to "Days alive out of hospital in heart failure: Insights from the PARADIGM-HF and CHARM trials" [Am Heart J 241 (2021) 108-119].
    Am Heart J. 2025;285:105.
    PubMed    


  14. ZEYMER U, Hassinger F, Bramlage P, Schafer A, et al
    Hyperoxemic Oxygen Therapy in Patients with Acute Anterior Myocardial Infarction: HOT-AAMI - Design and Rationale of a Randomized Trial.
    Am Heart J. 2025 Mar 21:S0002-8703(25)00095-X. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available


  15. YU J, Indraratna P, Briggs NE, Brown P, et al
    Rationale and design of the TeleClinical Care (TCC) -Cardiac trial: A pragmatic randomized trial of adjunctive virtual models of care in the secondary prevention of cardiovascular events.
    Am Heart J. 2025 Mar 11:S0002-8703(25)00091-2. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available


  16. DONAZZAN L, Bulian F, Maines M, Erckert M, et al
    Effect of rate-adaptive atrial support compared to VDD pacing in cardiac resynchronization therapy recipients: A randomized cross-over study.
    Am Heart J. 2025;281:149-156.
    PubMed     Abstract available


  17. HARRINGTON J, Leyva M, Rao VN, Oakes M, et al
    Implementing guideline-directed medical therapy: Stakeholder-identified barriers and facilitators.
    Am Heart J. 2025;281:23-31.
    PubMed     Abstract available


    February 2025
  18. TAKAHASHI T, Wei J, Iribarren AC, Gulati M, et al
    Rationale and design of the Women's Ischemia Syndrome Evaluation Mechanisms of Coronary Microvascular Dysfunction Leading to Pre-Heart Failure With Preserved Ejection Fraction (WISE Pre-HFpEF).
    Am Heart J. 2025 Feb 24:S0002-8703(25)00056-0. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available


  19. PASQUALIN G, Misra A, Gauvreau K, Sanders SP, et al
    Ventricular-Arterial Coupling is associated with Clinical Outcomes in Patients with Systemic Right Ventricle.
    Am Heart J. 2025 Feb 19:S0002-8703(25)00043-2. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available


  20. SHOJI S, Cyr DD, Hernandez AF, Velazquez EJ, et al
    Win Ratio Analyses Using a Modified Hierarchical Composite Outcome: Insights From PARAGLIDE-HF.
    Am Heart J. 2025;280:70-78.
    PubMed     Abstract available


    January 2025
  21. KREINBROOK J, Rego E, Schlichte L, Barnes S, et al
    Towards a Person-Centered After-Visit Summary to Facilitate Improved Heart Failure Care (HF-AVS): A Scoping Review and Call to Action.
    Am Heart J. 2025 Jan 29:S0002-8703(25)00014-6. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available


  22. BALDI C, Maio MD, Esposito L, Bellino M, et al
    How the COAPT trial affected the selection of patients with secondary mitral regurgitation undergoing transcatheter edge-to-edge repair: insights from the GIOTTO Registry.
    Am Heart J. 2025 Jan 27:S0002-8703(25)00011-0. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available


  23. CHAIKIJURAJAI T, Chen HH, Tang WHW
    Baseline NT-proBNP Non-Response Score and Health Status Measures in Assessing Treatment Responses in Heart Failure with Reduced Ejection Fraction.
    Am Heart J. 2025 Jan 25:S0002-8703(25)00012-2. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available


  24. SHECHTER A, Gupta A, Kaewkes D, Taheri H, et al
    Implications of an Off-Hours Setting in Patients Undergoing Transcatheter Edge-to-Edge Repair for Mitral Regurgitation.
    Am Heart J. 2025 Jan 2:S0002-8703(24)00341-7. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available


    December 2024
  25. BULLOCK G, Jacobs JA, Carey JR, Pan IZ, et al
    Patterns of diuretic titration during inpatient management of acute decompensated heart failure.
    Am Heart J. 2024 Dec 27:S0002-8703(24)00339-9. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available


  26. ZHOU K, Alemayehu W, Rathwell S, McAlister FA, et al
    The Relationship of Diuretics and Dietary Sodium in Patients with Heart Failure: An Analysis of the SODIUM-HF Trial.
    Am Heart J. 2024 Dec 4:S0002-8703(24)00321-1. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available


  27. HWANG CS, Desai RJ, Kesselheim AS, Levin R, et al
    Primary Medication Adherence in Medicare Beneficiaries Prescribed Sacubitril-Valsartan or Renin-Angiotensin System Blockers for Heart Failure with Reduced Ejection Fraction.
    Am Heart J. 2024 Dec 3:S0002-8703(24)00316-8. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available


    October 2024
  28. MAIDMAN SD, Blecker S, Reynolds HR, Phillips LM, et al
    Cardiologist Perceptions on Automated Alerts and Messages To Improve Heart Failure Care.
    Am Heart J. 2024 Oct 16:S0002-8703(24)00269-2. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available


  29. BALGOBIND A, Pierce M, Alviar C, Barnett C, et al
    Current practices in the management of temporary mechanical circulatory support: A survey of CICU directors in North America.
    Am Heart J. 2024;276:115-119.
    PubMed     Abstract available


    September 2024
  30. QAZI SU, Hamid A, Ansari HUH, Khouri MG, et al
    Trends in Cancer and Heart Failure related mortality in adult US population: A CDC WONDER database analysis from 1999 to 2020.
    Am Heart J. 2024 Sep 17:S0002-8703(24)00235-7. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available


  31. MEFFORD MT, Ambrosy AP, Wei R, Zheng C, et al
    Rule-based natural language processing to examine variation in worsening heart failure hospitalizations by age, sex, race and ethnicity, and left ventricular ejection fraction.
    Am Heart J. 2024 Sep 7:S0002-8703(24)00234-5. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available


  32. LITWIN SE, Komtebedde J, Borlaug BA, Kaye DM, et al
    Long term safety and outcomes after atrial shunting for heart failure with preserved or mildly reduced ejection fraction: 5-year and 3-year follow-up in the REDUCE LAP-HF I and II trials.
    Am Heart J. 2024 Sep 3:S0002-8703(24)00216-3. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available


  33. NELSON MD, Gomez-Arnold JM, Wei J, Lauzon M, et al
    Contributors to high left ventricular ejection fraction in women with ischemia and no obstructive coronary artery disease: Results from the Women's Ischemia Syndrome Evaluation - Coronary Vascular Dysfunction (WISE-CVD) Study.
    Am Heart J. 2024 Sep 2:S0002-8703(24)00224-2. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available


  34. BOCKUS LB, Shadman R, Poole JE, Dardas TF, et al
    Seattle proportional risk model in GISSI-HF: Estimated benefit of ICD in patients with EF less than 50.
    Am Heart J. 2024;275:35-44.
    PubMed     Abstract available


    August 2024
  35. LUNDBERG S, Knigge P, Strange JE, Nouhravesh N, et al
    Temporal trends in infection-related hospitalizations among patients with heart failure: A Danish nationwide study from 1997-2017.
    Am Heart J. 2024 Aug 29:S0002-8703(24)00219-9. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available


  36. ANDERSEN CF, Omar M, Larsen JH, Kistorp C, et al
    Accelerometer-Measured Physical Activity in Patients with Heart Failure and Reduced Ejection Fraction: Determinants and Relationship with Patient-Reported Health Status.
    Am Heart J. 2024 Aug 27:S0002-8703(24)00220-5. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available


  37. SANNA GD, Erre GL, Cameli M, Guerra F, et al
    Association of sex with in-hospital management and outcomes of patients with heart failure: data from the REAL-HF registry: The impact of sex in patients hospitalized for heart failure.
    Am Heart J. 2024 Aug 27:S0002-8703(24)00221-7. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available


  38. JIANG C, Wang Z, Du X, Wang Y, et al
    Protocol for a randomized controlled trial of intensive blood pressure control on cardiovascular risk reduction in patients with atrial fibrillation: rationale and design of the CRAFT trial.
    Am Heart J. 2024 Aug 23:S0002-8703(24)00203-5. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available


  39. FOX H
    Heart Failure and nocturnal hypoxemic burden, the connection is getting closer and closer.
    Am Heart J. 2024 Aug 21:S0002-8703(24)00207-2. doi: 10.1016/j.ahj.2024.
    PubMed    


  40. LABARCA G
    Novel markers of nocturnal hypoxemia in sleep apnea and heart failure with reduced ejection fraction (HFrEF).
    Am Heart J. 2024 Aug 16:S0002-8703(24)00202-3. doi: 10.1016/j.ahj.2024.
    PubMed    


  41. SOH CH, Wright L, Baumann A, Seidel B, et al
    Use of artificial intelligence-guided echocardiography to detect cardiac dysfunction and heart valve disease in rural and remote areas: Rationale and design of the AGILE-echo trial.
    Am Heart J. 2024;277:11-19.
    PubMed     Abstract available


  42. DISMORR M, Granbom-Koski M, Ellfors E, Ruck A, et al
    Sex differences and long-term clinical outcomes after transcatheter aortic valve replacement: a SWEDEHEART study.
    Am Heart J. 2024 Aug 9:S0002-8703(24)00185-6. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available


  43. MEDINA CK, Barnes SG, Felker GM, Mentz RJ, et al
    Severe obesity among patients with left ventricular assist devices.
    Am Heart J. 2024;274:130-133.
    PubMed     Abstract available


  44. ARRIGO M, Davison B, Edwards C, Adamo M, et al
    Characteristics, treatment, and outcomes of early vs. late enrollees of the STRONG-HF trial.
    Am Heart J. 2024;274:119-129.
    PubMed     Abstract available


    July 2024
  45. ABDUL-SAMAD K, Ma S, Austin DE, Chong A, et al
    Comparison of Machine Learning and Conventional Statistical Modeling for Predicting Readmission Following Acute Heart Failure Hospitalization.
    Am Heart J. 2024 Jul 31:S0002-8703(24)00183-2. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available


  46. BURGOS LM, Vila RCB, Ballari FN, Goyeneche A, et al
    Inferior vena CAVA and Lung UltraSound-guided therapy in Acute Heart Failure: a randomized pilot study (CAVAL US-AHF study).
    Am Heart J. 2024 Jul 31:S0002-8703(24)00181-9. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available


  47. SINGH K, Nikhare K, Gandral M, Aithal K, et al
    Rationale, Design and Baseline Characteristics of a Randomized Controlled Trial of a Cardiovascular Quality Improvement Strategy in India: The C-QIP Trial.
    Am Heart J. 2024 Jul 19:S0002-8703(24)00174-1. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available


  48. ELLFORS E, Dismorr M, Ruck A, Settergren M, et al
    Predicted prosthesis-patient mismatch and long-term clinical outcomes after transcatheter aortic valve replacement: a SWEDEHEART study.
    Am Heart J. 2024 Jul 18:S0002-8703(24)00175-3. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available


  49. PINNA GD, Maestri R, Robbi E, Guazzotti G, et al
    Nocturnal Hypoxemic Burden in Patients with Heart Failure: Emerging Prognostic Role of Its Non-Specific Component.
    Am Heart J. 2024 Jul 5:S0002-8703(24)00166-2. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available


    June 2024
  50. IBEH C, Kulick ER, Boehme AK, Friedman AM, et al
    Incident Stroke in Individuals with Peripartum Cardiomyopathy.
    Am Heart J. 2024 Jun 20:S0002-8703(24)00160-1. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available


  51. PICHAN CM, Santivasi WL, Mentz RJ
    A Bridge to Comfort: Palliative Inotrope Infusion for Patients with Heart Failure in Hospice Care.
    Am Heart J. 2024 Jun 15:S0002-8703(24)00159-5. doi: 10.1016/j.ahj.2024.
    PubMed    


    May 2024
  52. KUSNER J, Patel RB, Hu M, Bertoni AG, et al
    Association of Disproportionate Liver Fat with Markers of Heart Failure: The Multi-Ethnic Study of Atherosclerosis.
    Am Heart J. 2024 May 20:S0002-8703(24)00125-X. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available


  53. KITTIPIBUL V, Yaranov DM, Biegus J, Gray JM, et al
    Prognostic implications of volume status assessed by blood volume analysis in ambulatory heart failure.
    Am Heart J. 2024;271:178-181.
    PubMed     Abstract available


    April 2024
  54. ELKHOLEY K, Asad ZUA, Shehata E, Mustafina I, et al
    Association between atrial fibrillation and heart failure patient reported outcomes across the ejection fraction spectrum.
    Am Heart J. 2024 Apr 27:S0002-8703(24)00104-2. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available


  55. GAGNON LR, Hazra D, Perera K, Wang K, et al
    Uptake of SGLT2i and Outcomes in Patients with Diabetes and Heart Failure: A Population-Based Cohort and a Specialized Clinic Cohort.
    Am Heart J. 2024 Apr 24:S0002-8703(24)00094-2. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available


  56. HAMO CE, Mukhopadhyay A, Li X, Zheng Y, et al
    Association between Visit Frequency, Continuity of Care, and Pharmacy Fill Adherence in Heart Failure Patients.
    Am Heart J. 2024 Apr 13:S0002-8703(24)00090-5. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available


  57. KEEPANASSERIL A, Pande SN, Suriya Y, Baghel J, et al
    "Comparing the Outcomes of Rheumatic Heart Disease in Pregnancy Complicated with and without Atrial Fibrillation: A Propensity Score Matched Analysis".
    Am Heart J. 2024 Apr 11:S0002-8703(24)00089-9. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available


  58. MANJA V, Sandhu ATS, Asch S, Frayne S, et al
    Healthcare utilization and left ventricular ejection fraction distribution in methamphetamine use associated heart failure hospitalizations.
    Am Heart J. 2024;270:156-160.
    PubMed     Abstract available


  59. SMOLDEREN KG, Romain G, Cleman J, Scierka L, et al
    Variability in guideline-directed medical therapy across sites and operators and long-term mortality and amputation outcomes risk in patients undergoing peripheral vascular interventions.
    Am Heart J. 2024;270:75-85.
    PubMed     Abstract available


    March 2024
  60. ZHANG L, Wang W, Huo X, He G, et al
    Predicting the risk of 1-year mortality among patients hospitalized for acute heart failure in China.
    Am Heart J. 2024 Mar 13:S0002-8703(24)00066-8. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available


  61. SAMPAIO RODRIGUES T, Garcia Quarto LJ, Nogueira SC, Theuerle JD, et al
    Door-to-diuretic time and mortality in patients with acute heart failure: A systematic review and meta-analysis.
    Am Heart J. 2024;269:205-209.
    PubMed     Abstract available


    February 2024
  62. SZABO B, Benson L, Savarese G, Hage C, et al
    Previous heart failure hospitalization, spironolactone and outcomes in heart failure with preserved ejection fraction - a secondary analysis of TOPCAT.
    Am Heart J. 2024 Feb 25:S0002-8703(24)00048-6. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available


  63. RAO VN, Sharma A, Stebbins A, Buse JB, et al
    Regional variation in cause of death in patients with type 2 diabetes: insights from EXSCEL: Cause of Death in Type 2 Diabetes.
    Am Heart J. 2024 Feb 21:S0002-8703(24)00040-1. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available


  64. ANDERSEN CF, Larsen JH, Jensen J, Omar M, et al
    Empagliflozin to elderly and obese patients with increased risk of developing heart failure: Study protocol for the Empire Prevent trial program.
    Am Heart J. 2024 Feb 14:S0002-8703(24)00032-2. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available


  65. LAMP J, Wu Y, Lamp S, Afriyie P, et al
    Characterizing Advanced Heart Failure Risk and HemodyNAmic Phenotypes using Interpretable Machine Learning.
    Am Heart J. 2024 Feb 7:S0002-8703(24)00021-8. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available


    January 2024
  66. ZEITLER EP, Dalgaard F, Abraham WT, Cleland JGF, et al
    Benefit of cardiac resynchronization therapy among older patients: A patient-level meta-analysis.
    Am Heart J. 2024;267:81-90.
    PubMed     Abstract available


  67. ROLFS N, Huber C, Schwarzkopf E, Mentzer D, et al
    Clinical course and follow-up of pediatric patients with COVID-19 vaccine-associated myocarditis compared to non-vaccine-associated myocarditis within the prospective multicenter registry-"MYKKE".
    Am Heart J. 2024;267:101-115.
    PubMed     Abstract available


    December 2023
  68. SALERNO PR, Chen Z, Wass S, Motairek I, et al
    Sex-specific Heart Failure Burden Across the United States: Global Burden of Disease 1990-2019.
    Am Heart J. 2023 Dec 16:S0002-8703(23)00348-4. doi: 10.1016/j.ahj.2023.
    PubMed     Abstract available


  69. SIREN M, Leivo J, Anttonen E, Jolly SS, et al
    The Prognostic Significance of Single-Lead ST-Segment Resolution in ST-Segment Elevation Myocardial Infarction Patients Treated with Primary PCI - A Substudy of the Randomized TOTAL Trial.
    Am Heart J. 2023 Dec 16:S0002-8703(23)00347-2. doi: 10.1016/j.ahj.2023.
    PubMed     Abstract available


  70. MONTEMBEAU SC, Rao BR, Mitchell AR, Speight CD, et al
    Integrating Cost into Shared Decision-Making for Heart Failure with Reduced Ejection Fraction (POCKET-COST-HF): A Trial Providing Out-of-pocket Costs for Heart Failure Medications during Clinical Encounters.
    Am Heart J. 2023 Dec 12:S0002-8703(23)00322-8. doi: 10.1016/j.ahj.2023.
    PubMed     Abstract available


  71. GUNN AH, Warraich HJ, Mentz RJ
    Costs of Care and Financial Hardship Among Patients with Heart Failure.
    Am Heart J. 2023 Dec 6:S0002-8703(23)00330-7. doi: 10.1016/j.ahj.2023.
    PubMed     Abstract available


    November 2023
  72. SAVARESE G, Gatti P, Benson L, Adamo M, et al
    LEFT VENTRICULAR EJECTION FRACTION DIGIT BIAS AND RECLASSIFICATION OF HEART FAILURE WITH MILDLY REDUCED VS. REDUCED EJECTION FRACTION BASED ON THE 2021 DEFINITION AND CLASSIFICATION OF HEART FAILURE: Abbreviated title: DIGIT BIAS AND HEART FAILURE REC
    Am Heart J. 2023 Nov 14:S0002-8703(23)00317-4. doi: 10.1016/j.ahj.2023.
    PubMed     Abstract available


  73. STRANGE JE, Nouhravesh N, Schou M, Christensen DM, et al
    High-risk admission prior to transcatheter aortic valve replacement and subsequent outcomes: Preceding events and outcomes after TAVR.
    Am Heart J. 2023 Nov 14:S0002-8703(23)00311-3. doi: 10.1016/j.ahj.2023.
    PubMed     Abstract available


  74. SALAHUDDIN T, Hebbe A, Daus M, Essien UR, et al
    Trends and Site-level Variation of Novel Cardiovascular Medication Utilization among Patients Admitted for Heart Failure or Coronary Artery Disease in the US Veterans Affairs System: 2017-2021.
    Am Heart J. 2023 Nov 11:S0002-8703(23)00318-6. doi: 10.1016/j.ahj.2023.
    PubMed     Abstract available


    October 2023
  75. EGBE AC, Miranda WR, Jain CC, Stephens EH, et al
    Temporal Changes in Clinical Characteristics and Outcomes of Adults With Congenital Heart Disease.
    Am Heart J. 2023;264:1-9.
    PubMed     Abstract available


    September 2023
  76. FLETT A, Cebula A, Nicholas Z, Adam R, et al
    Rationale and study protocol for the BRITISH randomised trial (Using cardiovascular magnetic resonance identified scar as the Benchmark Risk Indication Tool for Implantable cardioverter defibrillators in patients with Non-Ischaemic Cardiomyopathy and
    Am Heart J. 2023 Sep 28:S0002-8703(23)00281-8. doi: 10.1016/j.ahj.2023.
    PubMed     Abstract available


    August 2023
  77. JAMES S, Erlinge D, Storey RF, McGuire DK, et al
    Rationale and design of the DAPA-MI trial: Dapagliflozin in patients without diabetes mellitus with acute myocardial infarction.
    Am Heart J. 2023 Aug 25:S0002-8703(23)00207-7. doi: 10.1016/j.ahj.2023.
    PubMed     Abstract available


  78. HARRINGTON J, Mentz RJ, Rockhold FW, Garg J, et al
    Baseline Characteristics of Patients in the Randomized Study to Investigate the Efficacy and Safety of Ferric Carboxymaltose as Treatment for Heart Failure with Iron Deficiency: HEART-FID Trial.
    Am Heart J. 2023 Aug 18:S0002-8703(23)00202-8. doi: 10.1016/j.ahj.2023.
    PubMed     Abstract available


  79. COX ZL, Siddiqi HK, Stevenson LW, Bales B, et al
    Randomized controlled trial of urinE chemiStry guided aCute heArt faiLure treATmEnt (ESCALATE): Rationale and design.
    Am Heart J. 2023 Aug 4:S0002-8703(23)00187-4. doi: 10.1016/j.ahj.2023.
    PubMed     Abstract available


    July 2023
  80. VINEREANU D, Wojdyla DM, Alexander JH, Lopes RD, et al
    Heart Rate and Death and Hospitalization for Heart Failure in Patients with Persistent or Permanent Atrial Fibrillation: Insights from the ARISTOTLE Trial.
    Am Heart J. 2023 Jul 26:S0002-8703(23)00179-5. doi: 10.1016/j.ahj.2023.
    PubMed     Abstract available


  81. MATASIC DS, Blumenthal RS, Fonarow GC, Gulati M, et al
    Taking the next step in cardiovascular risk reduction: Integrating heart failure and peripheral arterial disease prevention.
    Am Heart J. 2023 Jul 20:S0002-8703(23)00176-X. doi: 10.1016/j.ahj.2023.
    PubMed    


  82. BANKE A, Andersson C, D'Souza M, Fosbol E, et al
    Importance of familial predisposition to heart failure to the risk of anthracycline related cardiotoxicity: A nationwide study.
    Am Heart J. 2023 Jul 13:S0002-8703(23)00175-8. doi: 10.1016/j.ahj.2023.
    PubMed     Abstract available


  83. JEFFERIES JL, Kovesdy CP, Ronco C
    Contemporary laboratory assessment of acute cardiorenal syndrome for early diagnosis: A call for action.
    Am Heart J. 2023;261:75-84.
    PubMed     Abstract available


  84. PETERS AE, Solomon N, Chiswell K, Fonarow GC, et al
    Transthyretin Amyloid Cardiomyopathy Among Patients Hospitalized for Heart Failure and Performance of an Adapted Wild-Type ATTR-CM Machine Learning Model: Findings from GWTG-HF.
    Am Heart J. 2023 Jul 1:S0002-8703(23)00169-2. doi: 10.1016/j.ahj.2023.
    PubMed     Abstract available


    June 2023
  85. GANGAVELLI A, Liu Z, Wang J, Okoh A, et al
    Racial Differences in Low Natriuretic Peptide Levels: Implications for Heart Failure Clinical Trials.
    Am Heart J. 2023 Jun 19:S0002-8703(23)00163-1. doi: 10.1016/j.ahj.2023.
    PubMed     Abstract available


  86. VIOLI F, Castellani V, Menichelli D, Pignatelli P, et al
    GUT BARRIER DYSFUNCTION AND ENDOTOXEMIA IN HEART FAILURE: A DANGEROUS CONNUBIUM?
    Am Heart J. 2023 Jun 8:S0002-8703(23)00146-1. doi: 10.1016/j.ahj.2023.
    PubMed     Abstract available


  87. MEWTON N, Donal E, Picard F, Derimay F, et al
    Prognostic impact of precipitated cardiac decompensation in symptomatic heart failure with reduced ejection fraction and severe secondary mitral regurgitation.
    Am Heart J. 2023 Jun 2:S0002-8703(23)00137-0. doi: 10.1016/j.ahj.2023.
    PubMed     Abstract available


    May 2023
  88. KRONBORG MB, Frausing MHJP, Svendsen JH, Johansen JB, et al
    Does Targeted Positioning of the Left Ventricular Pacing Lead Towards the Latest Local Electrical Activation in Cardiac Resynchronization Therapy Reduce the Incidence of Death or Hospitalization for Heart Failure?
    Am Heart J. 2023 May 21:S0002-8703(23)00129-1. doi: 10.1016/j.ahj.2023.
    PubMed     Abstract available


  89. ARNOLD SV, Gosch K, Kosiborod M, Wong ND, et al
    Contemporary Use of Cardiovascular Risk Reduction Strategies in Type 2 Diabetes. Insights from The Diabetes Collaborative Registry.
    Am Heart J. 2023 May 8:S0002-8703(23)00112-6. doi: 10.1016/j.ahj.2023.
    PubMed     Abstract available


  90. CHOUAIRI F, Pinsker B, Miller PE, Fudim M, et al
    Effects of COVID-19 on Heart Failure Admissions.
    Am Heart J. 2023 May 6:S0002-8703(23)00111-4. doi: 10.1016/j.ahj.2023.
    PubMed     Abstract available


  91. SELAMET TIERNEY ES, Palaniappan L, Leonard M, Long J, et al
    Design and rationale of re-energize fontan: Randomized exercise intervention designed to maximize fitness in fontan patients.
    Am Heart J. 2023;259:68-78.
    PubMed     Abstract available


    April 2023
  92. RAO VN, Cyr D, Wruck L, Sanders G, et al
    Electronic Health Record Characterization and Outcomes of Heart Failure with Preserved Ejection Fraction.
    Am Heart J. 2023 Apr 26:S0002-8703(23)00100-X. doi: 10.1016/j.ahj.2023.
    PubMed     Abstract available


  93. FU G, Zhou Z, Jian B, Huang S, et al
    Systolic blood pressure time in target range and long-term outcomes in patients with ischemic cardiomyopathy.
    Am Heart J. 2023;258:177-185.
    PubMed     Abstract available


  94. JOHNSON M, Morrison FJ, McMahon G, Su M, et al
    Outcomes in patients with cardiometabolic disease who develop hyperkalemia while treated with a renin-angiotensin-aldosterone system inhibitor.
    Am Heart J. 2023;258:49-59.
    PubMed     Abstract available


  95. MUKHOPADHYAY A, Reynolds HR, Xia Y, Phillips LM, et al
    Design and pilot implementation for the BETTER CARE-HF trial: A pragmatic cluster-randomized controlled trial comparing two targeted approaches to ambulatory clinical decision support for cardiologists.
    Am Heart J. 2023;258:38-48.
    PubMed     Abstract available


    February 2023
  96. UPSHAW JN, Parker S, Gregory D, Koethe B, et al
    The effect of tablet computer-based telemonitoring added to an established telephone disease management program on heart failure hospitalizations: The Specialized Primary and Networked Care in Heart Failure (SPAN-CHF) III Randomized Controlled Trial.
    Am Heart J. 2023 Feb 24:S0002-8703(23)00042-X. doi: 10.1016/j.ahj.2023.
    PubMed     Abstract available


  97. YAKU H, Kato T, Morimoto T, Kaneda K, et al
    Rationale and Study design of the GOREISAN for Heart Failure (GOREISAN-HF) trial: A randomized clinical trial.
    Am Heart J. 2023 Feb 23:S0002-8703(23)00045-5. doi: 10.1016/j.ahj.2023.
    PubMed     Abstract available


    January 2023
  98. SILVAIN J, Cayla G, Ferrari E, Range G, et al
    betaeta Blocker Interruption after Uncomplicated Myocardial Infarction: Rationale and Design of the randomized ABYSS trial.
    Am Heart J. 2023 Jan 19:S0002-8703(23)00021-2. doi: 10.1016/j.ahj.2023.
    PubMed     Abstract available


    October 2021
  99. COTTER G, Davison BA, Edwards C, Senger S, et al
    Regional variation of effects of new antidiabetic medications in cardiovascular outcome trials.
    Am Heart J. 2021;240:73-80.
    PubMed     Abstract available


    June 2021
  100. SZUMMER K, Perino AC, Fan J, Kothari M, et al
    Association of kidney function and atrial fibrillation progression to clinical outcomes in patients with cardiac implantable electronic devices.
    Am Heart J. 2021 Jun 9. pii: S0002-8703(21)00149.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Chronic Heart Failure is free of charge.